FARMINGTON HILLS, Mich., Aug. 08, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of patients with retinal and refractive eye disorders, today announced that George Magrath, M.D., M.B.A., M.S., Chief Executive Officer, will present at the Canaccord Genuity 44th Annual Growth Conference, to take place in Boston, MA, August 14, 2024, and at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference, to take place virtually, on August 15, 2024.
| Event: | Canaccord Genuity 44th Annual Growth Conference |
| Location: | Boston, MA |
| Presenter: | Dr. George Magrath |
| Date: | August 14, 2024 |
| Time: | 9:00 a.m. ET |
| Format: | Fireside Chat |
| Event: | H.C. Wainwright 4th Annual Ophthalmology Virtual Conference |
| Location: | Virtual |
| Presenter: | Dr. George Magrath |
| Date: | August 15, 2024 |
| Time: | 10:30 a.m. ET |
| Format: | Presentation |
Company management will also be available for one-on-one meetings throughout the conferences. If you are interested in arranging a meeting, please contact your conference representative or send an email to ir@ocuphire.com.
About Ocuphire Pharma
Ocuphire Pharma, Inc. (Nasdaq: OCUP) is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of patients with retinal and refractive eye disorders. Ocuphire’s lead product candidate, APX3330, a novel small-molecule inhibitor of Ref-1 (reduction oxidation effector factor-1 protein), is in development for diabetic retinopathy. In addition, Ocuphire’s late-stage product candidate Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, is being developed for presbyopia and dim (mesopic) light vision disturbances and is currently approved and marketed by our partner as RYZUMVI™ for reversal of pharmacologically induced mydriasis. For more information, please visit www.ocuphire.com.
Contacts
| Corporate | Investor Relations |
| Nirav Jhaveri, M.B.A. CFO ir@ocuphire.com |
Corey Davis, Ph.D. LifeSci Advisors cdavis@lifesciadvisors.com |


Đề xuất
GovWare 2026 closes with a clear focus on securing AI that can act
Trip.com Malaysia secures win at Travel Daily Media Travel Trade Excellence Awards 2026 – Malaysia
ECI Group announces the successful start-up and operation of first HPPE plant
AMPERA and Berto Announce Proposed Business Combination to Accelerate Advanced Energy Technology Development and Commercialization
Mexican Influencer Max y Noelia Highlights Open Trade at the 9th CIIE While Touring Five APEC Economy Pavilions
Asia Pacific accounts for a third of the world’s fraud networks as identity fraud grows more complex: Sumsub